Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Condition(s):Multiple Myeloma; Refractory Multiple Myeloma; Multiple Myeloma in Relapse; RelapseLast Updated:October 29, 2021Recruiting
Hide Studies Not Open or Pending
Condition(s):Multiple Myeloma; Refractory Multiple Myeloma; Multiple Myeloma in Relapse; RelapseLast Updated:October 29, 2021Recruiting
Condition(s):Multiple MyelomaLast Updated:May 3, 2022Withdrawn
Condition(s):Multiple MyelomaLast Updated:February 20, 2024Active, not recruiting
Condition(s):Light Chain Deposition Disease; Primary Systemic AmyloidosisLast Updated:May 9, 2023Terminated
Condition(s):Plasma Cell MyelomaLast Updated:August 9, 2023Recruiting
Condition(s):Multiple MyelomaLast Updated:June 30, 2021Terminated
Condition(s):Multiple MyelomaLast Updated:August 22, 2022Recruiting
Condition(s):Amyloid; AL Amyloidosis; Refractory AL AmyloidosisLast Updated:July 6, 2023Recruiting
Condition(s):Relapsed/Refractory Multiple MyelomaLast Updated:January 10, 2024Active, not recruiting
Condition(s):Recurrent Plasma Cell Myeloma; Refractory Plasma Cell MyelomaLast Updated:August 4, 2023Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.